GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Cash-to-Debt

SNY (Sanofi) Cash-to-Debt : 0.29 (As of Jun. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Sanofi Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sanofi's cash to debt ratio for the quarter that ended in Jun. 2024 was 0.29.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Sanofi couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Sanofi's Cash-to-Debt or its related term are showing as below:

SNY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25   Med: 0.47   Max: 0.67
Current: 0.29

During the past 13 years, Sanofi's highest Cash to Debt Ratio was 0.67. The lowest was 0.25. And the median was 0.47.

SNY's Cash-to-Debt is ranked worse than
69.22% of 1017 companies
in the Drug Manufacturers industry
Industry Median: 0.97 vs SNY: 0.29

Sanofi Cash-to-Debt Historical Data

The historical data trend for Sanofi's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Sanofi Cash-to-Debt Chart

Sanofi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.50 0.50 0.63 0.49

Sanofi Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.63 0.38 0.49 0.29

Competitive Comparison of Sanofi's Cash-to-Debt

For the Drug Manufacturers - General subindustry, Sanofi's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Sanofi's Cash-to-Debt falls into.



Sanofi Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Sanofi's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Sanofi's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanofi  (NAS:SNY) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Sanofi Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Sanofi's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanofi Business Description

Address
46, avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.